Gilead Sciences (GILD) Tops Q2 EPS by 41c, Updates Guidance
Tweet
Share
E-mail
Get Alerts GILD Hot Sheet
EPS Growth %: -462.7%
Financial Fact:
Income from operations: 4.4B
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $2.56, $0.41 better than the analyst estimate of $2.15. Revenue for the quarter came in at $7.14 billion versus the consensus estimate of $6.35 billion.
GUIDANCE:
Gilead Sciences sees FY2017 revenue of $24-25.5 billion, versus the consensus of $24.8 billion.
Revised Full Year 2017 Guidance
Gilead revised its full year 2017 guidance, initially provided on February 7, 2017:
| (In millions, except percentages and per share amounts) | Initially Provided February 7, 2017 Reiterated May 2, 2017 | Updated July 26, 2017 | ||
| Net Product Sales | $22,500 - $24,500 | $24,000 - $25,500 | ||
| Non-HCV Product Sales | $15,000 - $15,500 | $15,500 - $16,000 | ||
| HCV Product Sales | $7,500 - $9,000 | $8,500 - $9,500 | ||
| Non-GAAP* | ||||
| Product Gross Margin | 86% - 88% | 86% - 88% | ||
| R&D Expenses | $3,100 - $3,400 | $3,200 - $3,400 | ||
| SG&A Expenses | $3,100 - $3,400 | $3,200 - $3,400 | ||
| Effective Tax Rate | 25.0% - 28.0% | 25.0% - 28.0% | ||
| Diluted EPS Impact of Acquisition-related, Up-front Collaboration, Stock-based Compensation and Other Expenses | $0.84 - $0.91 | $0.86 - $0.93 |
For earnings history and earnings-related data on Gilead Sciences (GILD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Cerebras Systems posts 94% revenue jump, announces OpenAI deal
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
